- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Zolinza
Synonyms :
vorinostat
Class :
Antineoplastics and HDAc Inhibitors
Dosage Forms & Strengths
capsule
100mg
Indicated for the treatment of CTCL, who have progressive, persistent, or recurrent disease on or followed by two systemic therapies :
400
mg
Orally
once a day
the dose is reduced to 300 mg orally per day if the patient is intolerant to therapy
the dose was further reduced to 300 mg once daily for five consecutive days each week if needed
continue the treatment until progressive disease or unacceptable toxicity occurs
Dose Adjustments
Renal Dose Adjustments:
Caution recommended.
Liver Dose Adjustments:
starting dose reduced to 300 mg orally once daily for mild to moderate hepatic impairment bilirubin 1-3 x ULN or AST > ULN
Data not available for severe hepatic impairment bilirubin > 3 x ULN
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, there may be an increased risk of adverse effects
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when used together, entrectinib and vorinostat both increase the QTc interval
when used together, encorafenib and vorinostat both increase the QTc interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, vorinostat reduces the effects of the cholera vaccine by immunosuppressive effects
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
It may enhance QTc interval when combined with lithium
when both drugs are combined, there may be increased toxicity of vorinostat by QTC interval
when both drugs are combined, there may be increased toxicity of vorinostat by QTC interval
Adverse drug reactions:
Frequency defined
>10%
Anorexia
Alopecia
Anemia
Peripheral edema
Headache
Pruritus
Cough
Chills
Constipation
Dry mouth
Dysguesia
Diarrhea
Fatigue
Nausea
Thrombocytopenia
Weight loss
Muscle spasms
Increase serum Cr
Dizziness
Vomiting
Upper respiratory infection
Decreased appetite
Pyrexia
<10%
Prolonged QT interval
Pulmonary embolism
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Pronunciation: vor-in-oh-stat
Use: It is an anti-cancer agent used to treat cutaneous T-cell lymphoma, multiple myeloma, and melanoma.